42744 Do Biologics for Psoriasis Prevent the Development of Psoriatic Arthritis? A population-based study
Kathleen H. Miao(Icahn School of Medicine at Mount Sinai), April W. Armstrong(University of California, Los Angeles), Margaret Y. Huang(University of Southern California), Hannah Peterson(Loma Linda University), Danielle Yee(University of Southern California), Kathryn Lee(Saint Louis University), Paige Kingston(Keck Hospital of USC), Khristina Lung(University of Southern California), Edwin Korouri(Rosalind Franklin University of Medicine and Science), Meredith D. Xepoleas(University of Southern California)
Cited by 3
Related Papers
Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics
|Journal of the American Academy of Dermatology|2019|917
Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with awareness and attention to comorbidities
|Journal of the American Academy of Dermatology|2019|484
Comparison of Biologics and Oral Treatments for Plaque Psoriasis
|JAMA Dermatology|2020|278
The time to offer treatments for COVID-19
|Expert Opinion on Investigational Drugs|2021|32
Deucravacitinib: A Novel TYK2 Inhibitor for the Treatment of Moderate-to-Severe Psoriasis
|Journal of Psoriasis and Psoriatic Arthritis|2023|25